Edition:
India

Boston Scientific Corp (BSX.N)

BSX.N on New York Stock Exchange

26.67USD
23 May 2017
Change (% chg)

$-0.13 (-0.49%)
Prev Close
$26.80
Open
$26.78
Day's High
$26.85
Day's Low
$26.61
Volume
1,200,507
Avg. Vol
1,804,246
52-wk High
$26.97
52-wk Low
$19.67

BSX.N

Chart for BSX.N

About

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health,... (more)

Overall

Beta: 1.11
Market Cap(Mil.): $35,552.19
Shares Outstanding(Mil.): 1,368.97
Dividend: --
Yield (%): --

Financials

BRIEF-Boston Scientific announces positive results from the Reprise III clinical trial

* The Boston Scientific LOTUS™ valve system demonstrated superior efficacy to Corevalve® in global reprise III trial at one year

16 May 2017

BRIEF-Boston Scientific closes Symetis acquisition

* To immediately begin selling Acurate TA and Acurate Neo/TF valve systems in Europe and other geographies outside of U.S. Source text for Eikon: Further company coverage:

16 May 2017

BRIEF-Boston Scientific says positive European registry results for WATCHMAN left atrial appendage closure device

* Boston scientific announces positive european registry results for watchman™ left atrial appendage closure device

12 May 2017

BRIEF-Boston Scientific announces results of study evaluating patients implanted with S-ICD System

* Announced results from U.S. post-market approval study evaluating 'real-world' patients implanted with S-ICD System

11 May 2017

India government panel rejects Boston Scientific plea on stent price caps

NEW DELHI Boston Scientific Corp stands to lose millions of dollars on its high-end heart stent in India after a government panel rejected its request to increase a cap on the price that it can charge for the device.

09 May 2017

BRIEF-Boston Scientific receives FDA approval for resonate family of high-voltage devices

* Boston Scientific receives U.S. FDA approval for resonate™ family of high-voltage devices

09 May 2017

BRIEF-Boston Scientific reports Q1 GAAP EPS $0.21

* Q1 interventional cardiology worldwide sales $605 million versus $560 million

27 Apr 2017

MEDIA-Abbott, Medtronic, Boston Scientific to recall new generation stents from India - Economic Times

- Note: Reuters has not verified this story and does not vouch for its accuracy

24 Apr 2017

BRIEF-Boston Scientific initiates global study to assess sudden cardiac arrest prevention therapy

* Boston Scientific initiates global study to assess sudden cardiac arrest prevention therapy in patients with diabetes who have previously experienced a heart attack

19 Apr 2017

Boston Scientific to expand in Europe with Symetis buy

Boston Scientific Corp on Thursday agreed to buy Swiss medical device maker Symetis SA for $435 million, looking to bolster its presence in Europe after recalling a range of heart valves in the region.

30 Mar 2017

More From Around the Web

Competitors

Earnings vs. Estimates